<!DOCTYPE html>
<html lang="en">
<head>
<?php $id='1911-1265'; include '../../seo.php';?>
<?php include '../../side-nav.php';?>
<div class="page-content">
<!--section-->
<div class="section mt-0">
<div class="breadcrumbs-wrap">
<div class="container">
<div class="breadcrumbs">
<a href="https://sprintdiagnostics.in/">Home</a>
<a href="https://www.sprintdiagnostics.in/hyderabad/test/">Test</a>
<span>AML Molecular Prognostication: FLT3, NPM1, and CEBPA </span>
</div>
</div>
</div>
</div>
<!--//section-->
<!--section-->
<div class="section page-content-first">
<div class="container mt-6">
<div class="row">
<div class="col-md-8 col-lg-8 mt-0 mt-md-0 mb-4">
<h1 class="test-h1">AML Molecular Prognostication: FLT3, NPM1, and CEBPA </h1>
<div class="post-text">
<p>Acute Myeloid Leukemia (AML) is a type of cancer that originates in the bone marrow and quickly affects the blood. It is characterized by the rapid growth of abnormal myeloid cells that interfere with the production of normal blood cells. In AML, mutations in specific genes play a crucial role in the behavior of the disease. The AML Molecular Prognostication panel, which tests for mutations in the FLT3, NPM1, and CEBPA genes, is critical in assessing the prognosis and guiding treatment decisions in AML.</p>

<p>FLT3 (FMS-like tyrosine kinase 3) gene mutations are among the most common in AML and are often associated with poor prognosis. NPM1 (Nucleophosmin 1) gene mutations, on the other hand, are typically associated with a more favorable prognosis. CEBPA (CCAAT/enhancer-binding protein alpha) mutations can also affect the course of the disease. This panel assesses mutations in all three genes, providing comprehensive genetic information that is vital for AML management.</p>
<div class="table-wrap">
<table class="table table-striped">
	<thead>
		<tr>
			<th scope="col">Test Name</th>
			<td scope="col">AML Molecular Prognostication: FLT3, NPM1, and CEBPA </td>
		</tr>
	</thead>
	<tbody>
		<tr>
			<th scope="row">Sample Type</th>
			<td>Bone Marrow / Blood</td>
		</tr>
		<tr>
			<th scope="row">Preparations Required</th>
			<td>No fasting is required for this test. However, it is crucial to inform your doctor about any medications or supplements you are currently taking.</td>
		</tr>
		<tr>
			<th scope="row">Report Time</th>
			<td>3 days</td>
		</tr>
		<tr>
			<th scope="row">Price in Hyderabad</th>
			<td>₹ 9900 </td>
		</tr>
	</tbody>
</table>
</div>
<div class="post-text">
<h2 class="test-h2 mt-3">What is the significance of the AML Molecular Prognostication panel in managing AML?</h2>
<p>The AML Molecular Prognostication panel is critical in providing information about the genetic makeup of AML. The
    presence or absence of mutations in FLT3, NPM1, and CEBPA genes significantly impacts the prognosis and helps in
    making informed decisions regarding the best treatment strategy.</p>
<h2 class="test-h2 mt-3">What are FLT3 gene mutations and how do they affect AML?</h2>
<p>FLT3 gene mutations are common in AML and result in the activation of FLT3 protein, which can cause the leukemia
    cells to grow uncontrollably. These mutations are generally associated with an aggressive form of AML and a poor
    prognosis.</p>
	<!--section achieved-->
	<?php include "../../include/iconsbox.php" ?>
	<!--//section achieved-->

<h2 class="test-h2 mt-3">How do NPM1 mutations influence AML?</h2>
<p>NPM1 mutations are typically associated with a more favorable outcome in AML. They are known to have a distinct
    pattern of genetic abnormalities and a better response to chemotherapy.</p>
<h2 class="test-h2 mt-3">What is the role of CEBPA mutations in AML?</h2>
<p>CEBPA mutations can be associated with a favorable prognosis in some cases of AML. However, the presence of other
    mutations can modify this effect. It's essential to assess CEBPA mutations in the context of other genetic
    abnormalities.</p>
<h2 class="test-h2 mt-3">How is the sample for this test collected?</h2>
<p>The sample is usually collected from the blood or bone marrow. The bone marrow sample is typically collected through
    a bone marrow aspiration procedure.</p>
<h2 class="test-h2 mt-3">What does a normal result look like?</h2>
<p>Normal results would indicate the absence of the specific mutations associated with AML in the FLT3, NPM1, and CEBPA
    genes. However, the interpretation should be performed by a doctor who will consider the patient's overall clinical
    picture.</p>
<h2 class="test-h2 mt-3">What should I do if my test results are abnormal?</h2>
<p>If your test results are abnormal, it's important to consult your doctor to discuss the next steps. Your doctor will
    interpret the results and may recommend additional testing or treatment options based on the genetic makeup of the
    AML.</p>
<h2 class="test-h2 mt-3">How often should this test be done?</h2>
<p>This test is usually done at diagnosis to establish the genetic profile of the AML. It may be repeated during
    treatment if necessary to monitor the disease, especially if there is a suspected change in the genetic
    characteristics of the leukemia cells.</p>
<h2 class="test-h2 mt-3">Can this test alone be used to diagnose AML?</h2>
<p>No, this test is not used alone for the diagnosis of AML. It is used in conjunction with other tests such as blood
    counts, bone marrow biopsy, and additional genetic testing to establish an AML diagnosis.</p>
<h2 class="test-h2 mt-3">Which doctor should I consult if my AML Molecular Prognostication results are abnormal?
</h2>
<p>You should consult a hematologist or oncologist if your AML Molecular Prognostication results are abnormal.</p>
<h2 class="test-h2 mt-3">Can this test be used to monitor the effectiveness of treatment?</h2>
<p>Yes, this test can be used to monitor the genetic characteristics of leukemia cells during treatment, which may help
    in assessing the effectiveness of treatment.</p>
<h2 class="test-h2 mt-3">What factors can affect the results of this test?</h2>
<p>Medications, underlying health conditions, and the technique of sample collection can affect the results of this
    test.</p>
<h2 class="test-h2 mt-3">How does this test help in personalized treatment for AML?</h2>
<p>By identifying the specific mutations present in an individual’s AML cells, the test helps doctors to tailor the
    treatment plan according to the genetic profile, thereby offering a more targeted and effective treatment approach.
</p>
<h2 class="test-h2 mt-3">Are there any risks associated with this test?</h2>
<p>The risks associated with this test are minimal and mainly related to the bone marrow aspiration procedure if
    performed. These might include pain, infection, or bleeding at the aspiration site.</p>
<h2 class="test-h2 mt-3">Can lifestyle or environmental factors influence the mutations tested in this panel?</h2>
<p>While lifestyle and environmental factors can play a role in the development of AML, the mutations tested in this
    panel are generally acquired during a person’s lifetime and are not typically influenced by external factors.</p>
<p>Understanding the genetic makeup of Acute Myeloid Leukemia through the AML Molecular Prognostication panel is
    critical in predicting the course of the disease and in making informed treatment decisions. This panel, which tests
    for mutations in FLT3, NPM1, and CEBPA, provides valuable information that can help tailor a personalized treatment
    plan for patients. It is essential for patients to communicate closely with their doctor to understand the
    implications of the test results and to participate actively in decision-making for their care.</p>
 
</div>		
</div>			
</div>
<!--form section-->
<?php include "../../include/bookslot.php" ?>
<!--form section-->
</div>
</div>
<!--//section-->
</div>
</div>
<?php include '../../footer.php';?>
</body>
</html>